(MedPage Today) — Alzheimer’s patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to…
Source link : https://www.medpagetoday.com/meetingcoverage/ctad/118850
Author :
Publish date : 2025-12-05 15:57:00
Copyright for syndicated content belongs to the linked Source.
